Paysign (PAYS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 7, 2025, to elect seven directors, approve executive compensation, determine say-on-pay frequency, and ratify the independent auditor.
Proxy materials and annual report for 2024 are available online, with voting encouraged via internet, mail, or in person.
Record date for voting is March 10, 2025, with 53,747,674 shares outstanding.
Voting matters and shareholder proposals
Proposals include election of seven directors, advisory vote on executive compensation, advisory vote on frequency of say-on-pay (Board recommends every three years), and ratification of Moss Adams LLP as auditor.
Board recommends voting FOR all proposals and a triennial say-on-pay vote.
Shareholders can submit proposals for the 2026 meeting by November 27, 2025, for inclusion in proxy materials.
Board of directors and corporate governance
Board consists of seven members, with four independent directors as defined by Nasdaq.
Board committees: Audit, Compensation, and Nominating and Corporate Governance, all comprised of independent directors.
Board leadership combines CEO and Chairman roles for unified strategy and accountability.
Directors attended at least 75% of meetings in 2024; all attended the 2024 annual meeting.
Nominating Committee considers diversity, experience, and independence in director selection.
Latest events from Paysign
- Rapid growth in patient affordability and tech-driven margin expansion offset plasma headwinds.PAYS
The MicroCap Rodeo Conference - NYC3 Feb 2026 - Strong revenue growth and market expansion in healthcare-focused prepaid payment solutions.PAYS
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 revenue up 30% year-over-year, net income positive, and 2024 guidance raised.PAYS
Q2 20242 Feb 2026 - Patient affordability business is rapidly scaling, driving strong growth and margin expansion.PAYS
Sidoti Micro-Cap Virtual Conference2 Feb 2026 - Q3 2024 revenue up 23%, pharma patient affordability revenue up 219% year-over-year.PAYS
Q3 202416 Jan 2026 - 2024 revenue up 23.5%, patient affordability soared 214.5%, 2025 outlook strong.PAYS
Q4 202425 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and say-on-pay frequency.PAYS
Proxy Filing1 Dec 2025 - Record Q2 revenue and profit, driven by pharma growth, margin expansion, and raised guidance.PAYS
Q2 202523 Nov 2025 - Proprietary tech, high retention, and innovation drive strong growth and positive analyst outlook.PAYS
17th Annual Southwest IDEAS Conference20 Nov 2025